De novo AML refers to AML in patients with no clinical history of prior myelodysplastic syndrome (MDS), myeloproliferative disorder, or exposure to potentially leukemogenic therapies or agents (Cheson et al., 2003). AML is diagnosed when at least 20% of the bone marrow cellularity is blasts (Vardiman et al., 2009).
APL is now considered a highly curable disease, with 2-year event-free survival rates of 75–84%. Early mortality is common in APL and is frequently related to hemorrhagic complications.
In contrast, leukostasis (also called symptomatic hyperleukocytosis) is a medical emergency most commonly seen in patients with acute myeloid leukemia or chronic myeloid leukemia in blast crisis. It is characterized by an extremely elevated blast cell count and symptoms of decreased tissue perfusion.
In most people with APML, treatment with ATRA and arsenic trioxide leads to a remission. Some people with high white cell counts may also need intravenous chemotherapy. Samples of your bone marrow may be tested for a genetic change known as PML-RARA.
C92.40 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM C92. 40 became effective on October 1, 2020.
Promyelocytic leukemia/retinoic acid receptor alpha or PML-RARA refers to an abnormal fusion gene sequence. It is a specific rearrangement of genetic material from two separate chromosomes (chromosomal translocation) and is associated with a specific type of leukemia.
All-Trans Retinoic Acid (ATRA)ATRA targets and eliminates the PML/RARα abnormality. This treatment causes a marked decrease in the concentration of leukemic blast cells in the marrow, and a remission frequently follows. Used alone, ATRA can induce a short-term remission in at least 80 percent of patients.
In the hippocampus, retinoic acid plays important physiological roles in synaptic plasticity, learning and memory, and adult neurogenesis. In the retina, retinoic acid acts as a light-signaling neuromodulator and regulates gap junction-mediated coupling of retinal neurons.
Acute promyelocytic leukemia (APL) M3 is an acute myeloid leukemia (AML) subtype characterized by proliferation of malignant promyelocytes with mature myeloid immunophenotype and the translocation t(15;17)(q22;q11), which results in the fusion of retinoic acid receptor-alpha (RARalpha) gene on chromosome 17 and the
Differentiation Syndrome is a complication of all-trans retinoic acid (ATRA) therapy in patients with acute promyelocytic leukemia (APML). It appears clinically as acute end-organ damage with peripheral edema, hypotension, acute renal failure, and interstitial pulmonary infiltrates.
Retinoic acid is synthesized from vitamin A (retinol) and found in embryos and adult vertebrates. Because animals are unable to produce vitamin A, they obtain this vitamin in the form of carotenoids from plants or retinyl esters derived from animal products.
Retinoic acid is a metabolite of vitamin A that mediates the vitamin's functions.
It happens when there are too many of the blood-forming cells called promyelocytes in the blood and bone marrow. A buildup of promyelocytes leads to a shortage of other kinds of blood cells, including red cells, white cells, and platelets. APL usually occurs in middle-aged adults, but it can happen at any age.
Because of advances in diagnostic techniques and modern treatments, APL is today considered to be the most curable subtype of acute myeloid leukemia in adults, with complete remission rates of 90 percent and cure rates of approximately 80 percent and even higher among low-risk patients.
Without treatment, survival is usually measured in days to weeks. With current treatment regimens, 65%–70% of people with AML reach a complete remission (which means that leukemia cells cannot be seen in the bone marrow) after induction therapy. People over the age of 60 usually have a lower response rate.
Treatment outcomes for APL are very good, and it is considered the most curable type of leukemia. Cure rates are as high as 90%.
Although AML is a serious disease, it is treatable and often curable with chemotherapy with or without a bone marrow/stem cell transplant (see the Types of Treatment section). It is important to remember that statistics on the survival rates for people with AML are an estimate.
Prognosis and Prognostic FactorsApproximately 60% to 70% of adults with AML can be expected to attain CR status after appropriate induction therapy. More than 25% of adults with AML (about 45% of those who attain CR) can be expected to survive 3 or more years and may be cured.
AML is diagnosed when the bone marrow contains 20 percent or more immature cells called blasts — a normal bone marrow has less than 5 percent blasts — determined to be myeloid in nature. Additional tests are performed to confirm the diagnosis and reveal the exact AML subtype.
Acute promyelocytic leukemia (APL) has become a curable disease by all-trans retinoic acid (ATRA)-based induction therapy followed by two or three courses of consolidation chemotherapy. Currently around 90% of newly diagnosed patients with APL achieve complete remission (CR) and over 70% of patients are curable.
The main treatment for most types of AML is chemotherapy, sometimes along with a targeted therapy drug. This might be followed by a stem cell transplant. Other drugs (besides standard chemotherapy drugs) may be used to treat people with acute promyelocytic leukemia (APL).
